Bell2Bell’s latest podcast features Hugh Rogers, CEO and Director of XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT).

As discussed in the podcast, XPhyto Therapeutics recently received ISO certification for its rapid point-of-care COVID-19 PCR diagnostic test.

“We expect to be in the market very soon, within 30 days, pending European approval right now,” Rogers said. “Testing is highly relevant and will be for many years to come. The virus is endemic. It appears that it will be a forever problem. It will be active at all times for the foreseeable future somewhere in the world, and testing is a major part of managing that situation. The rollout of vaccines will not be uniform across the globe. There will be significant discrepancies, primarily for logistical and economic reasons, between the developing world and the developed world. Any time there’s international travel, and in particular between jurisdictions with disparity of economic comfort or success, there’s going to be this need for ongoing testing.”


Download(Loading)